Health & Wellness Community

The initiative by the Municipal Corporation of Delhi (MCD) to utilize drones for mosquito fogging in areas prone to breeding these insects has faced delays despite a trial run conducted last week. According to a recent report from the MCD released on Monday, there were 105 new cases reported last week up until Saturday, whereas the entire month of July had seen 121 cases. The drone project was temporarily suspended due to safety concerns leading up to Independence Day, as stated by an official. The official further explained that all preparations have been made for the drone initiative, and the plan is to kick off the operation after August 15th. Each drone is capable of carrying 30 liters of insecticide, which would enable the targeted spraying of hard-to-reach areas like lakes, canals, and riverfront vicinity. The focus of this effort is to combat mosquito breeding in such areas. A notable trial run took place on August 1st, where the public health department employed a drone to spray anti-larvae mixture in the Usmanpur region. This trial aimed to address areas with a high concentration of dengue cases reported during the previous week. The cumulative count of dengue cases in the city has reached 348 so far, as opposed to 174 cases in 2022, 22 cases in 2021, 35 cases in 2020, and 47 cases in 2019. The situation underscores the concern, especially given the previous year’s total of 75 cases in the entirety of August, 72 cases in 2021, and 47 cases in 2020. Authorities noted that mosquito breeding has been exacerbated in outer Delhi regions due to waterlogging. The official emphasized that community support is crucial to effectively address this issue and urged everyone to prevent waterlogging in their surroundings and terraces. Moreover, instances of malaria have seen a significant rise, with a total count of 85 cases compared to 35 cases in 2022, 24 cases in 2021, and 45 cases in 2020. Thirteen malaria cases were recorded in the past week alone, as per the official. However, the occurrence of chikungunya has been relatively low, with only one case reported last week and a total of 15 cases, contrasting with nine cases in 2022 and 13 cases in 2021. To combat the spread of vector-borne diseases, the MCD has launched a comprehensive campaign. This initiative involves training and deploying a specialized workforce, including Asha workers, safai karamcharis (sanitation workers), and nullah beldars (drainage workers). These efforts will complement the work of 3,000 domestic breeding checkers. Each ward will now have a dedicated team of three nullah beldars and three safai karamcharis who are trained to identify and eliminate potential breeding grounds for disease-carrying vectors, the official stated.

In a ground-breaking revelation, a novel technique has emerged to predict health outcomes for critically ill patients experiencing circulatory shock. These patients, grappling with compromised heart function leading to inadequate blood and oxygen circulation due to factors like heart failure, sepsis, or bleeding, are often in dire need of close monitoring and tailored treatment. This innovative approach, the brainchild of a collaborative effort between Massachusetts General Hospital (MGH) and MIT, could significantly revolutionize the management of these cases, potentially reducing mortality rates and improving overall health prospects. The breakthrough findings have been documented in the prestigious journal Nature Medicine. The crux of this development revolves around the measurement of a vital circulatory parameter called critical closure pressure. This pressure delineates the point at which minute blood capillaries collapse, halting blood flow. Despite its potential to indicate blood vessel responsiveness in the face of disease and treatment, critical closure pressure has remained largely unexplored in clinical contexts. This study embarked on a journey of innovation by harnessing high-resolution waveform data obtained from blood pressure monitoring of over 5,500 patients housed in the cardiac intensive care unit at MGH. Researchers ingeniously devised an analysis based on various measurable parameters, encompassing arterial pressure, pulse pressure, and heart rate, to accurately define critical closure pressure. Intriguingly, they then introduced a novel parameter known as tissue perfusion pressure, calculated as the disparity between average arterial blood pressure and critical closure pressure. Astonishingly, this tissue perfusion pressure turned out to be an exceptional predictor of critical health outcomes for patients – gauging the risk of mortality, length of hospital stay, and the peak level of blood lactate, an indicator of tissue oxygenation. In the words of the study’s senior author, Aaron Aguirre, MD, PhD, a distinguished cardiologist and critical care expert at MGH, as well as an assistant professor of Medicine at Harvard Medical School, “When treating patients with circulatory shock, it is essential to maintain adequate blood pressure targets, yet standard goals are not personalised to individual patients. We have developed a new metric that can identify individuals with inadequate tissue perfusion who are at risk for adverse outcomes. We believe this method can be used to optimise treatment decisions for patients in the intensive care unit.”

Health Minister Mansukh Mandaviya is set to launch the e-CARe (e-Clearance for Afterlife Remains) portal, a groundbreaking initiative to expedite the repatriation of deceased Indians from foreign countries. The portal’s primary goal is to establish a 24×7 Designated Nodal officer, ensuring swift scrutiny and approval within a 48-hour timeframe. This move aims to bring uniformity to the entire process, eliminating any subjectivity previously present in the procedures conducted by Airport Health Offices (APHOs). The e-CARe portal offers numerous advantages, including round-the-clock accessibility, faster clearance, instant messaging for easy tracking, increased accountability, and flexibility in application submission. It allows any family member of the deceased to apply and become the consignee, not solely relying on the airlines. Moreover, it streamlines coordination among multiple stakeholders through a single interface. The functioning of the portal involves timely intimations sent via email, SMS, and WhatsApp to relevant parties, including the Central International Health Division, Nodal Officer, APHOs, consignees, and airlines. During the initial 48 hours, updates are provided every 12 hours for the first 36 hours, followed by escalations every four hours for the subsequent 12 hours to prevent any clearance delays. Stakeholders can conveniently track the application status through the e-CARe portal using a registration number. The e-CARe Portal ensures seamless coordination and transparency throughout the repatriation procedure. The final verification of original documents will take place at the respective arrival airport by the concerned APHO, ensuring a well-regulated and efficient process.

A breakthrough in the world of pharmaceuticals emerges from a Gujarat-based company, Asprius Lifesciences, as they unveil a potential game-changer in the treatment of diabetic neuropathy. This prevalent condition, affecting millions globally, leads to nerve damage in peripheral regions, resulting in numbing sensations, tingling, pain, and weakness in the extremities. The innovative treatment, a fixed-dose combination (FDC) of two drugs, holds great promise and has already been patented by the company. Spearheaded by the visionary Chairman & MD, Vishal Zinzuwadia, and backed by the brilliant mind of Dr. Sanjay Agrawal, Medical Director of Asprius Lifesciences, this novel formulation offers new hope to those battling diabetic neuropathy. Recognizing the severe impact of diabetic neuropathy on patients’ quality of life, the company is now diligently conducting clinical trials to assess the safety and efficacy of their revolutionary FDC. If successful, the treatment will soon be available in India, marking a significant milestone in the fight against this debilitating condition. With the potential to mitigate symptoms and prevent further complications, this cutting-edge development signifies a crucial step forward in addressing diabetic neuropathy’s unmet medical needs. Asprius Lifesciences’ dedication to improving patients’ lives serves as a beacon of hope for countless individuals seeking relief from the burdens of diabetic neuropathy.

The Lok Sabha was informed that India has seen remarkable progress in its medical education sector since 2014. The country has witnessed an 82% increase in the number of medical colleges, growing from 387 to 704, and an impressive 110% increase in MBBS seats, rising from 51,348 to 1,07,948 during this period. Furthermore, there has been a substantial 117% rise in the number of post-graduate (PG) medical seats, from 31,185 to 67,802. Union Health Minister Mansukh Mandaviya highlighted the government’s efforts in supporting the establishment of new medical colleges in underserved areas and aspirational districts. A total of 101 medical colleges have been approved under the centrally-sponsored scheme, with one such college approved in Assam. The government’s initiatives also aimed at upgrading existing medical colleges to enhance medical education standards. Through various schemes, support has been provided to add thousands of MBBS and PG seats in different colleges across the country. Additionally, the National Medical Commission Act, 2019, was introduced to improve access to quality medical education and ensure the availability of skilled medical professionals throughout India. The Act has led to several positive changes, including recognizing the Diplomate of National Board qualification for faculty appointments and increasing the age limit for certain medical college positions to 70 years. Furthermore, the NMC Act has relaxed norms for setting up medical colleges, rationalized the teacher-student ratio to increase PG seats, and framed guidelines for determining fees in private medical institutions and deemed-to-be universities. India’s medical education sector has seen significant expansion and improvements, contributing to better healthcare access and quality across the nation.

According to a recent survey conducted by GlobalData, the use of artificial intelligence (AI) in healthcare is on the rise, with 49% of healthcare industry professionals with prior AI experience strongly endorsing its application in clinical practice and administrative tasks. The survey, which took place between March 2023 and June 2023 and involved 426 healthcare industry professionals, highlights the increasing integration of AI into healthcare provision. GlobalData’s latest report titled ‘AI in Clinical Practice – Physician Perspective 2023’ reveals that diagnostics support and treatment decision support are the two most popular use cases for AI tools in healthcare. Practices like oncology are already leveraging AI for tasks such as risk prediction and disease diagnosis. However, it is emphasized that scientific validation is crucial to verify the accuracy and reliability of AI-generated results. The report also indicates that physicians are increasingly comfortable with using AI for automating administrative tasks, signifying a growing acceptance of AI’s value in streamlining healthcare operations across major pharmaceutical markets, including the US, France, Germany, Italy, Spain, the UK, Japan, and China (8MM). China has emerged as a leading player in embracing AI within the global healthcare landscape, driven by its commitment to improving healthcare accessibility and quality. By embracing AI, China is positioning itself as a key player in the ongoing digital revolution in the healthcare industry. AI’s application in drug development, such as target identification and drug repurposing, has shown promising outcomes, boosting confidence in AI tools. As AI continues to evolve rapidly and the demand for improved healthcare delivery grows, GlobalData predicts a gradual shift towards more extensive AI adoption in clinical practices.

Alzheimer’s disease experts have unveiled a ground-breaking development in the way doctors diagnose patients with this progressive brain disorder. At an Alzheimer’s Association conference in Amsterdam, they introduced a new rating system that mirrors the numerical staging system used in cancer diagnoses. This system replaces the previous guidelines issued in 2018 and aims to provide a more accurate and comprehensive assessment of the disease’s progression. The motivation behind this update stems from recent advancements in detecting key Alzheimer’s-related proteins, such as beta amyloid, in the blood. These advancements, along with the emergence of new treatments that require confirmation of disease pathology, prompted experts to revamp the diagnostic guidelines. The new system considers both cognitive changes and the presence of abnormal biomarkers, offering a more holistic view of the individual’s underlying disease. Gone are the terms “mild,” “moderate,” and “severe,” which were previously used to describe the stages of Alzheimer’s. Instead, patients will now receive a score ranging from 1 to 7, reflecting the extent of cognitive changes and the presence of abnormal disease biomarkers. Additionally, the system introduces four biological stages labelled a, b, c, and d. These stages provide further granularity in assessing the progression of the disease. The new rating system also includes a Stage 0 category for individuals who carry genes that guarantee the development of Alzheimer’s. This category encompasses people with Down Syndrome, as they have a significantly higher risk of developing Alzheimer’s later in life. By incorporating this additional stage, the guidelines acknowledge the diverse factors contributing to the development of the disease. Dr. Clifford Jack of the Mayo Clinic, the lead author of the report, emphasizes the similarity of the new system to cancer stages, highlighting that the goal is to provide a more precise understanding of the disease. The updated guidelines are particularly timely, as doctors prepare to identify and treat patients with recently approved drugs such as Leqembi and donanemab. The proposed guidelines are intended for doctors to utilize in clinical practice, equipping them with a more nuanced approach to diagnosing and treating Alzheimer’s patients. By enabling personalized medicine, which considers specific biomarkers and disease stages, doctors can now offer treatments that aim to slow down the progression of the disease, rather than solely managing its symptoms. These draft guidelines are currently open for expert review and comment, ensuring that the input of the Alzheimer’s research community is considered. The final version will reflect this feedback, marking a significant step forward in accurately diagnosing and managing Alzheimer’s disease. With its devastating impact on memory and cognitive abilities, Alzheimer’s presents a pressing challenge, and this new rating system represents a vital advancement in the fight against this debilitating condition.  

The Directorate General of Health Services’ (DGHS) Medical Counselling Committee (MCC) has announced that the counselling process for medical and dental courses in India will tentatively begin on July 20. The schedule released by the MCC pertains to the online counselling for NEET-UG in seats under the all-India quota, deemed universities, central universities, all AIIMS institutes, and JIPMER. While students can start registering from July 20 and filling their choices from July 22, participating institutes will verify the tentative seat matrix on July 20 and 21. Although the centralised counselling process was expected to include state seats as well, it will remain voluntary for the first year. The Ministry of Health and Family Welfare is in discussions with state counselling authorities to ensure a unified and transparent admission process. However, the notification lacks clarity on the schedule for state admissions, causing confusion and concerns among parents and students. The compressed timeline for the counselling process raises worries about the potential difficulties faced by parents and the possibility of meritorious students missing out on their preferred seats. The Ministry official clarified that DGHS handles only the all-India quota seats, and the NMC is expected to announce the state schedule separately.

The Indian government has taken strict measures against several pharmaceutical companies for failing to comply with quality control standards. Production of drugs has been halted at 31 firms, while the licenses of 50 firms have been cancelled or suspended. Additionally, 73 firms have received showcause notices, and 21 firms have been issued warning letters. These actions come as a result of a nationwide inspection of drug manufacturing units that were identified as being at risk of producing substandard, adulterated, or counterfeit drugs. The inspections were prompted by recent controversies involving the alleged adulteration of certain products, particularly cold and cough syrups exported abroad. To ensure compliance with the Drugs & Cosmetics Act, 1940 and its rules, a committee comprising two joint drug controllers has been established at the Central Drug Standard Control Organisation headquarters to oversee the inspection process, reporting, and subsequent actions. On the matter, Union Minister of Chemicals and Fertilisers, Mansukh Mandaviya, held a meeting with representatives from various pharmaceutical companies, stressing the importance of maintaining drug quality and urging small and medium-sized pharma companies to adopt good manufacturing practices through self-regulation. Mandaviya also instructed the Drug Controller General of India (DCGI) to take strong action against any companies involved in producing counterfeit drugs, emphasizing that the quality of drugs manufactured in India should not be compromised.

Researchers at Washington University in St. Louis have developed an innovative air monitor capable of detecting different variants of the SARS-CoV-2 virus in a room within approximately five minutes. This affordable device combines advanced aerosol sampling technology with an ultrasensitive biosensing technique. The monitor, described as the most sensitive detector available, has the potential to be used in hospitals, healthcare facilities, schools, and public spaces to detect SARS-CoV-2 and monitor other respiratory virus aerosols like influenza and respiratory syncytial virus (RSV). The research team published their findings in the journal Nature Communications, emphasizing the current lack of tools to assess room safety. The new device aims to provide real-time information, enabling individuals to know within minutes whether there is a live virus present. John Cirrito, a professor of neurology at Washington University, highlighted the importance of immediate knowledge, particularly in crowded settings where delayed confirmation of potential illness could have serious consequences. To develop the monitor, the researchers modified a micro-immunoelectrode (MIE) biosensor that was initially designed to detect amyloid beta, a biomarker for Alzheimer’s disease. They replaced the amyloid beta antibody with a nanobody derived from llamas that recognizes the spike protein of the SARS-CoV-2 virus. This nanobody-based electrochemical approach offers faster detection without requiring extensive processing steps or reagents, making it more efficient. The nanobody itself is small, easy to produce and modify, and cost-effective. The biosensor was integrated into an air sampler that utilizes wet cyclone technology. This sampler creates a surface vortex by mixing high-velocity air with fluid, effectively trapping virus aerosols. The sampler’s automated pump collects the fluid and sends it to the biosensor for seamless virus detection using electrochemistry. This wet cyclone sampler stands out due to its ability to sample a larger volume of air in just five minutes, significantly increasing virus recovery compared to other commercially available samplers. The team conducted tests in the apartments of two COVID-positive patients, comparing real-time PCR results of air samples from the bedrooms with those from a virus-free control room. The monitor successfully detected RNA from the virus in the bedroom air samples while yielding negative results for the control air samples. In laboratory experiments simulating a room-sized chamber with aerosolized SARS-CoV-2, the wet cyclone sampler and biosensor efficiently detected various levels of airborne virus concentrations after just a few minutes of sampling. This ground-breaking air monitor addresses the challenge of detecting diluted virus particles in indoor air, a task that even pushes the limits of polymerase chain reaction (PCR) detection. The research team’s innovation and use of advanced technology offer a promising solution for real-time monitoring of viral presence in various environments, facilitating timely interventions to mitigate transmission risks. Source: PTI